Olendalizumab

Modify Date: 2024-01-11 09:39:49

Olendalizumab structure	Common Name	Olendalizumab
	CAS Number	2210314-30-8	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Olendalizumab

Olendalizumab (ALXN1007) is a mouse-derived and humanized IgG2-G4-κ antibody, targeting to Complement protein C5a (Ki=60 pM). Olendalizumab targets the complement inflammatory pathway. Moreover, Olendalizumab can be used for research of complement mediated disorder caused by corona virus[1][2].

Name	Olendalizumab

Description	Olendalizumab (ALXN1007) is a mouse-derived and humanized IgG2-G4-κ antibody, targeting to Complement protein C5a (Ki=60 pM). Olendalizumab targets the complement inflammatory pathway. Moreover, Olendalizumab can be used for research of complement mediated disorder caused by corona virus[1][2].
Related Catalog	Research Areas >> Infection Signaling Pathways >> Immunology/Inflammation >> Complement System
Target	Complement protein C5a[1]
In Vitro	Olendalizumab 可用作生物素化捕获试剂，在 Bioaffy wash 1 中的工作浓度为 100 μg/mL，同时 AlexaFluor 标记的抗 C5a 克隆 2942 在 Rexxip F 中的工作浓度为 4 μg/mL[1]。补体系统的成员，如 C3、C5a、C5b-9，包括受体，如 C3aR 和 C5aR，介导病毒感染后的肺损伤。此外，C5/C5a 更是冠状病毒引起的肺损伤中的非沉默补体。Olendalizumab 是有效的 C5a 抑制剂[2]。
References	[1]. Dysinger M, et al. A Gyrolab Assay for the Quantitation of Free Complement Protein C5a in Human Plasma. AAPS J. 2018 Oct 2;20(6):106. [2]. Annane D, et al. Methods for treating a complement mediated disorder caused by viruses. World Intellectual Property Organization, WO2021211940 A1. 2021-10-21.

No Any Chemical & Physical Properties

Olendalizumab

Use of Olendalizumab

Names

Olendalizumab Biological Activity

Chemical & Physical Properties